Collegium Pharmaceutical, Inc.

Historical 13F Holders

Symbol
COLL
CUSIP
19459J104
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 19459J104 since 12/18/2024, newest first.

Filer % of Class Filed
Integrated Core Strategies (US) LLC 13G/A Amendment 1
7.4% 10/8/2026
Event 9/30/2026
Integrated Core Strategies (US) LLC 13G
5.6% 8/24/2026
Event 8/17/2026
Fuller & Thaler Asset Management, Inc. 13G 5.0% 8/14/2026
Event 6/30/2026
Principal Global Investors 13G 5.0% 8/5/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.0% 7/31/2026
Event 6/30/2026
Eventide Asset Management, LLC 13G/A Amendment 8
4.5% 5/15/2026
Event 3/31/2026
Janus Henderson Group PLC 13G 5.8% 5/15/2026
Event 3/31/2026
Renaissance Technologies LLC 13G/A Amendment 1
4.5% 5/14/2026
Event 1/8/2026
Integrated Core Strategies (US) LLC 13G
4.7% 5/12/2026
Event 5/7/2026
Invesco Ltd. 13G 5.0% 5/8/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 5 0% 3/26/2026
Event 3/13/2026
Eventide Asset Management, LLC 13G/A Amendment 7
5.9% 2/13/2026
Event 12/31/2025
Rubric Capital Management LP 13G/A Amendment 2
4.7% 2/13/2026
Event 12/31/2025
Renaissance Technologies LLC 13G
5.1% 11/13/2025
Event 9/8/2025
Renaissance Technologies LLC 13G/A Amendment 1
4.8% 8/13/2025
Event 4/1/2025
Principal Global Investors 13G/A Amendment 1 4.6% 8/11/2025
Event 6/30/2025
Invesco Ltd. 13G/A Amendment 1 4.9% 8/7/2025
Event 6/30/2025
Rubric Capital Management LP 13G/A Amendment 1
9.3% 5/14/2025
Event 3/31/2025
Pacer Advisors, Inc. 13G/A Amendment 1
1.1% 5/2/2025
Event 3/31/2025
Pacer Advisors, Inc. 13G
5.4% 5/2/2025
Event 12/31/2024
BlackRock, Inc. 13G/A Amendment 8 15.6% 4/28/2025
Event 3/31/2025
Rubric Capital Management LP 13G
7.3% 2/13/2025
Event 12/31/2024
Invesco Ltd. 13G 5.5% 2/7/2025
Event 12/31/2024
Renaissance Technologies LLC 13G
5.1% 11/13/2024
Event 8/2/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 7 142 k $3.10 M
2026 Q2 286 41.0 M $1.81 B
2026 Q1 268 38.0 M $1.26 B
2025 Q4 285 38.7 M $1.79 B
2025 Q3 248 37.2 M $1.30 B
2025 Q2 228 35.9 M $1.06 B
2025 Q1 248 36.7 M $1.10 B
2024 Q4 243 37.1 M $1.06 B
2024 Q3 257 38.8 M $1.50 B
2024 Q2 238 40.4 M $1.30 B
2024 Q1 238 41.5 M $1.61 B
2023 Q4 201 40.7 M $1.25 B
2023 Q3 178 38.7 M $866 M
2023 Q2 183 39.2 M $843 M
2023 Q1 204 39.4 M $946 M
2022 Q4 188 37.4 M $868 M
2022 Q3 175 37.8 M $608 M
2022 Q2 162 36.4 M $646 M
2022 Q1 178 36.1 M $734 M
2021 Q4 162 35.9 M $671 M
2021 Q3 155 36.4 M $719 M
2021 Q2 159 39.0 M $921 M
2021 Q1 169 39.0 M $924 M
2020 Q4 148 37.9 M $760 M
2020 Q3 145 39.0 M $812 M
2020 Q2 154 37.4 M $655 M
2020 Q1 166 37.0 M $603 M
2019 Q4 141 31.9 M $657 M
2019 Q3 122 31.5 M $362 M
2019 Q2 140 31.9 M $420 M
2019 Q1 151 31.5 M $477 M
2018 Q4 125 34.1 M $585 M
2018 Q3 135 33.7 M $495 M
2018 Q2 142 31.3 M $744 M
2018 Q1 148 30.7 M $782 M
2017 Q4 107 28.5 M $526 M
2017 Q3 77 26.0 M $273 M
2017 Q2 77 24.5 M $307 M
2017 Q1 89 24.2 M $244 M
2016 Q4 92 23.4 M $365 M
2016 Q3 72 15.9 M $306 M
2016 Q2 76 14.7 M $174 M
2016 Q1 71 14.9 M $270 M
2015 Q4 61 11.9 M $327 M
2015 Q3 49 10.2 M $227 M
2015 Q2 46 9.28 M $165 M